McDermott advises STADA on cooperation with Calliditas concerning the marketing of special therapy for IgA nephropathy in Europe


Frankfurt/Munich, July 23, 2021 – McDermott Will & Emery advised STADA Arzneimittel AG on a license agreement to register and commercialize a novel specialty drug candidate for the treatment of the chronic autoimmune kidney disease Immunoglobulin A Nephropathy (IgAN). The cooperation extends to the European Economic Area, Switzerland and the United Kingdom. It has a total value of EUR 97.5 million ($ 115 million) plus royalties.

STADA relies on a three-pillar strategy consisting of generics, specialty pharmaceuticals and non-prescription consumer healthcare products. STADA sells products in about 120 countries worldwide. Calliditas is a Nasdaq-listed clinical-stage pharmaceutical company based in Sweden and focusing on the development of orphan drugs.

The McDermott team advising STADA was led by Deniz Tschammler (Commercial/Regulatory, Munich) and Monika Richter (Life Sciences/Licensing, Frankfurt) and worked very closely with STADA’s inhouse team which comprised Christoph C. Dengler (EVP Global Legal / General Counsel), Marcus Heppner (Director Legal Affairs – Global BD&L and M&A) and Friederike Bockmann (Senior Legal Counsel).

About McDermott

McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective — and often unexpected — solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.

Media Contacts